Litcius/Paper detail

Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists

André Scheen

2022Diabetes & Metabolism32 citationsDOI

Topics & Concepts

MedicineAtrial fibrillationHeart failureStroke (engine)Internal medicineCardiologyAtrial flutterDiabetes mellitusPlaceboEndocrinologyMechanical engineeringPathologyAlternative medicineEngineeringDiabetes Treatment and ManagementAtrial Fibrillation Management and OutcomesAntiplatelet Therapy and Cardiovascular Diseases
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists | Litcius